Form 4: Esperion Therapeutics Director Tracy M. Woody Acquires Stock Options

Sentiment:

SEC Form 4 Filing


Director Tracy M. Woody acquired 65,000 stock options in Esperion Therapeutics, Inc. on May 23, 2024.

Summary

  • On May 23, 2024, Tracy M. Woody, a director of Esperion Therapeutics, Inc., acquired 65,000 stock options.
  • The options have an exercise price of $2.25.
  • The options vest in full on the earlier of May 23, 2025, or the Issuer's next annual meeting of stockholders following May 23, 2024.
  • The options expire on May 23, 2034.
  • Following the transaction, Woody directly owns 65,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

  • A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

  • The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates

DateDescription
May 26, 2022Date of execution for the Limited Power of Attorney.
May 23, 2024Date of the stock option transaction.
May 24, 2024Date of signature for the Form 4 filing.
May 23, 2025First possible vesting date for the stock options.
May 23, 2034Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.